A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors AstraZeneca
- 21 Jul 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.